Physician profile
Robert C Cartwright
NPI 1326129230
$169,018.90
in general payments reported to CMS, 2019-2025
37 companies · $2,546 in 2025
The $2,546 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,345 · 2020: $14K · 2021: $56K · 2022: $59K · 2023: $23K · 2024: $7,357 · 2025: $2,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $6,372 · Travel and Lodging: $144 · Education: $23.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Food and Beverage | $6,371.57 |
| Travel and Lodging | $144.10 |
| Education | $23.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $151,938.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Optinose US, INC. | $4,460.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $3,395.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,855.85 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,325.89 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,047.38 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $564.81 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $552.62 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $510.96 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Csl Behring | $347.19 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Abbvie INC. | $338.53 | 2021-2024 | Rinvoq |
| Pfizer INC. | $279.52 | 2019-2025 | |
| Amgen INC. | $223.81 | 2022-2025 | Tezspire |
| Kaleo, INC. | $188.93 | 2019-2023 | Auvi-Q |
| Incyte Corporation | $126.93 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $109.86 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Lilly USA, LLC | $105.67 | 2024-2025 | Ebglyss, Taltz |
| Teva Pharmaceuticals USA, INC. | $94.03 | 2019-2023 | Cinqair |
| Alk-Abello, INC | $77.26 | 2022 | |
| Shire North American Group INC | $77.14 | 2019 | |
| Aimmune Therapeutics, INC. | $67.53 | 2020-2022 | |
| Blueprint Medicines Corporation | $49.75 | 2024 | Ayvakit |
| Adma Biomanufacturing LLC | $49.36 | 2022 | |
| Pharming Healthcare, INC. | $41.05 | 2021-2022 | |
| Horizon Therapeutics Plc | $31.48 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $22.08 | 2025 | Sajazir |
| Dermavant Sciences, INC. | $20.21 | 2024 | Vtama |
| Leo Pharma INC. | $18.32 | 2022 | |
| Merck Sharp & Dohme LLC | $18.15 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $17.74 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $17.39 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.59 | 2021 | |
| Phadia US INC. | $15.00 | 2021 | |
| Octapharma USA, INC. | $13.08 | 2024 | Cutaquig |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.